Clear, Defensible Medical Necessity for Every Test

Molecular labs face increasing payer scrutiny on PCR infectious-disease testing and pharmacogenomics (PGx). Our patho-pharmacology practice performs chart-level reviews to determine whether a molecular test is medically necessary before it is ordered.

We evaluate:

• Symptom documentation and clinical context

•  Prior cultures, PCRs, and recent treatment

• Risk factors and guideline-supported indications

• Drug–diagnosis mismatches or outdated/missing labs

This ensures PCR is used appropriately versus traditional culture and sensitivity, and that PGx is justified based on drug-gene risks, treatment failure, or high-risk medication profiles. Labs get defensible utilization. Providers get clarity.

Pathologist-Led Interpretation Designed for Busy Providers

Molecular results only create value when clinicians know exactly what they mean.
Our pathologists deliver concise, treatment-ready interpretations for:

• Infectious disease PCR results, including organism load and clinical significance

• Resistance gene profiles

• PGx phenotypes and drug-metabolism implications

• Confounding factors such as polypharmacy or renal/hepatic impairment

Reports are written to reduce cognitive load. Providers receive a clear “what this means” summary and actionable guidance tied to clinical standards.

Antibiotic Streamlining and PGx-Based Medication Optimization

Most clinicians do not have time to reconcile complex molecular findings with multi-drug regimens, resistance patterns, and PGx variants.
We close that gap by providing:

• Antibiotic selection and de-escalation guidance

•  Avoid-use and adjust-dose recommendations

• Drug–drug and drug–gene interaction assessments

• Therapy streamlining to reduce side-effects, treatment failure, and unnecessary cost

This allows providers to use your molecular panels confidently without needing to research each case.

A Compliant Alternative to Lab-Funded “Clinical Consulting”

Labs cannot legally pay providers, pharmacists, or software vendors to influence testing behavior or support prescribing—this creates Anti-Kickback Statute (AKS) risk.
Our model removes that exposure.

• We contract directly with the ordering providers or groups—not the lab.

• We provide independent medical-necessity review, interpretation, and pharmacology consulting.

• No remuneration flows from the lab to the prescriber.

• Labs gain increased provider confidence and appropriate utilization without compliance risk.

Your lab can grow responsibly, providers can rely on expert interpretation, and all services remain cleanly separated from inducement concerns.

The Outcome

Molecular labs gain higher-value testing, reduced denials, and stronger provider adoption.Providers receive simplified, expert-driven guidance without compliance concerns.Patients get safer, more effective therapy.